Quantcast
Last updated on April 19, 2014 at 18:42 EDT

Latest Daiichi Sankyo Stories

2014-01-08 08:28:54

TOKYO, SEATTLE, and LEBANON, N.H., Jan. 8, 2014 /PRNewswire/ -- Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas. Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets....

2014-01-07 12:28:27

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO and MUNICH, Jan. 7, 2014 /PRNewswire/ -- Daiichi Sankyo, Company Limited (hereafter, Daiichi Sankyo) today announced that the Marketing Authorization Application (MAA) for its investigational, oral, once-daily direct factor Xa-inhibitor edoxaban has been submitted to the European Medicines Agency...

2013-12-19 08:26:43

-- Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism TOKYO, Dec. 19, 2013 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has submitted a supplemental New Drug Application (NDA) for its oral, once-daily direct factor Xa-inhibitor LIXIANA(®) (Edoxaban Tosilate Hydrate) for review by the Japanese Ministry...

2013-12-09 08:29:05

- VTE patients with cancer treated with once-daily edoxaban had a numerically lower incidence of recurrent VTE and a 36% lower risk of clinically relevant bleeding compared to warfarin in a subgroup analysis of the phase 3 Hokusai-VTE study(1) NEW ORLEANS and TOKYO, Dec. 9, 2013 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced results of a prespecified subgroup analysis of 771 cancer patients enrolled in the phase 3 Hokusai-VTE study. Patients with...

2013-12-05 23:04:28

Reportbuyer.com just published a new market research report: Drug Delivery Partnering Terms and Agreements. London (PRWEB) December 05, 2013 The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals....

2013-12-02 08:31:59

Surveyed Oncologists Report that Yervoy Holds Most Second-Line Patient Share in the BRAF-Mutation-Positive Population, According to a New Report from BioTrends Research Group EXTON, Pa., Dec. 2, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q3 2013, Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf, on average, garners 50 percent patient...

2013-11-26 08:28:16

Surveyed Oncologists Indicate that Yervoy Holds the Most Patient Share in the First-Line BRAF Wild-Type Population, According to a New Report from BioTrends Research Group EXTON, Pa., Nov. 26, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, according to oncologists surveyed in Q3 2013, Roche/Genentech/Daiichi Sankyo/Chugai's Zelboraf is the patient share leader in the...

2013-11-13 23:19:48

Reportbuyer.com just published a new market research report: PharmaSphere: Asia Pacific Deal Trends, 2004–2013. London (PRWEB) November 13, 2013 PharmaSphere: Asia Pacific Deal Trends, 2004–2013 Summary GlobalData’s report, "PharmaSphere: Asia Pacific Deal Trends, 2004–2013" offers an in-depth understanding of the key deals that took place in the region during the last decade. The type of deals covered in the report include Mergers & Acquisitions (M&A), Licensing...

2013-10-28 08:28:43

Company To Pursue Next Stage of Development as Part of Collaboration with Daiichi Sankyo and Baxter REDWOOD CITY, Calif., Oct. 28, 2013 /PRNewswire/ -- Coherus Biosciences, Inc. today announced that its proposed etanercept biosimilar molecule, CHS-0214, an investigational drug, met the primary endpoint of clinical pharmacokinetic (PK) similarity to Enbrel(®) in a confirmatory clinical study in healthy subjects meeting US, EU, and Japanese regulatory requirements for clinical PK...

2013-10-22 12:25:09

More Than Three-Quarters of Non-Prescribers Anticipate Prescribing Tafinlar and Mekinist Within the Next Six Months, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 22, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that at one month post-launch, approximately one-quarter of surveyed U.S. medical oncologists have prescribed GlaxoSmithKline's BRAF-inhibitor...